Stents polymers

First author (reference) Year Type of stent Polymer Model Control Thrombosis reduction Neointima reduction... 

First author Year (reference) Type of stent Polymer Model Drug Amount Control stent Thr-R Neo-R... 

Massey, S., E. Gallino, P. Cloutier et al. 2010. Low-energy electrons and x-ray irradiation effects on plasma-polymerized allylamine bioactive coatings for stents. Polym Degrad Stab 95 153-163. 

Cardiovascular coronary artery disease targeting late stent thrombosis PLEA stent Polymer blend with P(MPC3o-co-BMA7o) 48,49... 

Bioabsorbable polymeric stents can trigger acute or chronic inflammatory responses due to the degradation of the stent. The vascular response to a fully bioabsorbable stent can be more different than that of a metal- or polymer-coated stent. Polymers are listed in Table 7.5. Anti-inflammatory drugs are listed in Table 7.6. 

Bittl, J. A., 2014. Deconstructing stent polymers. Journal of the American College of Cardiology 63 (4), 308-309. 

Hopkins, C., McHugh, P.E., O Dowd, N.P., Rochev, Y., McGarry, J.P., 2013. A combined computational and experimental methodology to determine the adhesion properties of stent polymer coatings. Comput. Mater. Sci. 80, 104—112. 

Initial tests in the rat revealed a high degree of tissue compatibility of Dat-Tyr-Hex derived polymers. More detailed tests are now in progress. In addition, tyrosine derived polymers are currently being evaluated in the formulation of an intracranial controlled release device for the release of dopamine, in the design of an intraarterial stent (to prevent the restenosis of coronary arteries after balloon angioplasty), and in the development of orthopedic implants. The use of tyrosine derived polymers in these applications will provide additional data on the biocompatibility of these polymers. 

See also Smart polymers applications of, 22 355 biodegradable networks of, 22 364 cyclic and thermomechanical characterization of, 22 358—362 defined, 22 355-356 examples of, 22 362-364 molecular mechanism underlying, 22 356-358, 359t Shape-memory rings, 22 351 Shape-memory springs, in virtual two-way SMA devices, 22 346-347 Shape-memory stents, 22 352 Shape, of fiber polymers, 77 174-175. 

Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004 350 221-231. 

Siloxane-containing devices have also been used as contact lenses, tracheostomy vents, tracheal stents, antireflux cuffs, extracorporeal dialysis, ureteral stents, tibial cups, synovial fluids, toe joints, testes penile prosthesis, gluteal pads, hip implants, pacemakers, intra-aortic balloon pumps, heart valves, eustachian tubes, wrist joints, ear frames, finger joints, and in the construction of brain membranes. Almost all the siloxane polymers are based on various polydimethylsiloxanes. 

Artificial biologies, whelher soff or hard, can be categorized as eifher temporary (short term) or permanent (long term) in their intended application. Most, but certainly not all, polymers for biomedical applications are of the short-term type and include sutures, drug delivery devices, temporary vascular grafts and stents, tissue scaffolds. 

Originality Although diazeniumdiolated polymers have been used in vascular stents,... 

Preparation of a diazeniumdiolated polymer-coated vascular stent... 

Based on the needs of certain application, the polymer should demonstrate versatile mechanical properties [e.g., stent coatings require polymers to be elastomeric and microsphere processing require them to have high glass transition temperature (7 )]. 

Farb A, Heller PR Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent, Circulation 2001 104 473 79. 

Colombo A, DrzewieckiJ, Banning A, etal, Randomized study to assess the effectiveness of slow- and moderate-release polymer based pac I itaxe I-eluting stents for coronary artery lesions, Circulation 2003 108 788-794. 

Fontaine AB, BorsaJJ, Dos Passos S, et al. Evaluation of local abciximab delivery from the surface of a polymer-coated covered stent in vivo canine studies. J Vase Interv Radiol 2001 12(4) 487-492. 

Lambert T Dev V Rechavia E, Forrester J, Litvak p Eigler N. Localized arterial wall drug delivery from a polymer-coated removable metallic stent kinetics, distribution, and bioactivity offorskolin. Circulation 1994 90 1003-101 I. 

Buergler JM, Tio FO, Schulz DG, et al. Use of nitric-oxide-eluting polymer-coated coronary stents for prevention of restenosis in pigs, Coron Artery Dis 2000 I I (4) 351 -357. 

Sheth S, Dev V Jacobs H, et al. Prevention of subacute stent thrombosis by polymer-polyethylene oxide-heparin coating in rabbit carotid artery [abstr]. J Am Coll Cardiol 1995 25 348A. 

Baron JH, Aggrawal R, de Bono D, GershlickAH, Adsorption and elution of c7E3 Fab from polymer-coated stents in-vitro [abstr], Eur Heart J 1997 I 8(suppl) 503,... 

Baron JH, GershlickAH, Hogrefe K, et al, In vitro evaluation of c7E3-Fab (ReoPro) eluting polymer-coated coronary stents. Cardiovasc Res 2000 46(3) 585-594. 

---